



# Pharmaids Pharmaceuticals Limited

PPL/BSE/Q3/87/2018-19

Date: 12.02.2019

To  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P.J. Towers, Dalal Street,  
Mumbai - 400 001

**Scrip Code:** 524572

Dear Sir,

**Sub: Outcome of Board Meeting held on 12<sup>th</sup> February, 2019 - reg**


Pursuant to Reg. 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Tuesday, the 12<sup>th</sup> day of February, 2019 had inter-alia:


- Approved the Un-audited Financial Results for the quarter and Nine Months ended 31<sup>st</sup> December, 2018.

The meeting commenced at 11.00 a.m. and concluded at 1.30 p.m. You are requested to take the same on record.

Thanking you.

Yours faithfully,  
**For Pharmaids Pharmaceuticals Limited**

  
**Authorised Signatory**



CIN No. L52520TG1989PLC009679

Regd. Office : 4-4-211/212/3, Inder Bagh, Sultan Bazar, Hyderabad - 500 095. TELANGANA (INDIA)  
Ph : 040-6666 9809. email : mailpharmaids@yahoo.co.in, Website : www.pharmaids.com

Name of the Company PHARMAIDS PHARMACEUTICALS LIMITED

Statement of Profit and Loss for the Quarter ended 31st December, 2018

Rs. In lakhs

	Particulars	Note No.	Qtr. Ended		Qtr. Ended		Qtr. Ended		Year Ended	
			Un-audited 31.12.2018	Un-audited 30.09.2018	Un-audited 31.12.2017	Nine month ended Un- audited 31.12.2018	Audited 31.03.2017	Year Ended Audited 31.03.2018		
I	Revenue From Operations		48.10	-	17.32	48.10	120.25	44.91		
II	Other Income		0.03	0.25	0.41	0.29	1.01	2.01		
III	Total Income (I+II)		48.13	0.25	17.73	48.39	121.26	46.92		
IV	EXPENSES									
	Cost of materials consumed		-	-	-	-	64.49	3.47		
	Purchases of Stock-in-Trade		35.62	-	16.03	35.62	-	24.19		
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress		-	-	0.06	-	2.95	21.78		
	Employee benefits expense		1.13	1.33	1.14	3.32	16.63	6.30		
	Finance costs		0.12	0.11	0.03	0.23	4.01	0.14		
	Depreciation and amortization expense		0.02	0.02	0.02	0.06	6.37	0.11		
	Other expenses		7.75	7.84	8.63	18.31	70.53	27.79		
	Total expenses (IV)		44.64	9.30	25.91	57.54	164.98	83.77		
V	Profit/(loss) before exceptional items and tax (III- IV)		3.49	(9.05)	(8.18)	(9.15)	(43.72)	(36.86)		
VI	Exceptional Items		-	-	-	-	51.97	-		
VII	Profit/(loss) before tax (V+VI)		3.49	(9.05)	(8.18)	(9.15)	8.25	(36.86)		
VIII	Tax expense:									
	(1) Current tax Adj. of earlier year		-	-	-	-	-	1.73		
	(2) Deferred tax		-	-	-	-	(2.72)	(0.02)		
IX	Profit (Loss) for the period from continuing operations (VII-VIII)		3.49	(9.05)	(8.18)	(9.15)	10.97	(38.57)		
X	Profit/(loss) from discontinued operations		-	-	-	-	-	-		
XI	Tax expense of discontinued operations		-	-	-	-	-	-		
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)		-	-	-	-	-	-		
XIII	Profit/(loss) for the period (IX+XII)		3.49	(9.05)	(8.18)	(9.15)	10.97	(38.57)		
XIV	Other Comprehensive Income		-	-	-	-	-	-		
	A (i) Items that will not be reclassified to profit or loss		-	-	-	-	-	-		
	(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-	-	-	-	-		
	B (i) Items that will be reclassified to profit or loss		-	-	-	-	-	-		
	(ii) Income tax relating to items that will be reclassified to profit or loss		-	-	-	-	-	-		
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)		-	-	-	-	-	-		
XVI	Earnings per equity share (for continuing operation):									
	(1) Basic		0.10	(0.27)	(0.24)	(0.27)	0.32	(1.13)		
	(2) Diluted		0.10	(0.27)	(0.24)	(0.27)	0.32	(1.13)		
XVII	Earnings per equity share (for discontinued operation):									
	(1) Basic									
	(2) Diluted									
XVIII	Earnings per equity share (for discontinued & continuing operations)									
	(1) Basic									
	(2) Diluted									

*[Handwritten Signature]*  


**Notes:**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 12th February, 2019. 2. The Un-Audited Financial Results for the Quarter 3 and ended 31st December, 2018 have been prepared and reviewed by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013. 3. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison. a. 4) The company operates in a single segment and the results pertain to a single segment. i.e., drug formulation only.

**Reconciliation between net profit or loss reported in accordance with Indian GAAP (previous GAAP) and Ind AS for the quarter ended 31st December, 2018 and year ended 31 March 2018 is as follows:**

Particulars	Quarter Ended			Nine months ended 31.12.2018	Year ended	
	31.12.2018	30.09.2018	31.12.2017		31.03.2017	31.03.2018
	(Unaudited)	(Unaudited)	(Unaudited)		(Audited)	(Audited)
Net profit reported for the quarter earlier as per the previous Indian GAAP	3.49	(9.05)	(8.18)	(9.15)	10.97	(38.57)
Net profit for the period as per Ind AS	3.49	(9.05)	(8.18)	(9.15)	10.97	(38.57)
Other Comprehensive Income	-	-	-	-	-	-
Total Comprehensive Income for the period as per Ind AS	3.49	(9.05)	(8.18)	(9.15)	10.97	(38.57)

For PHARMAIDS PHARMACEUTICALS LIMITED

Place : Hyderabad

Date : 12-02-2019

*G. Venkatesh*  
MANAGING DIRECTOR

*Ch. Venkatesh*

*Ch. Venkatesh Modak  
R. S. S. S.*

Name of the Company **PHARMAIDS PHARMACEUTICALS LIMITED**  
Balance Sheet as at 31st December, 2018

(Rs in Lakhs)

	Particulars	Note No.	Figures as at the end of 31.12.2018	Figures as at the end of 31.03.2018
	1	2	3	4
<b>1</b>	<b>ASSETS</b>			
	<b>Non-current assets</b>			
	(a) Property, Plant and Equipment		0.33	0.23
	(b) Capital work-in-progress		-	-
	(c) Investment Property		-	-
	(d) Goodwill		-	-
	(e) Other Intangible assets		-	-
	(f) Intangible assets under development		-	-
	(g) Biological Assets other than bearer plants		-	-
	(h) Financial Assets			
	(i) Investments		-	-
	(ii) Trade receivables		-	-
	(iii) Loans		-	-
	(iv) Others (to be specified)		-	-
	(i) Deferred tax assets (net)		-	0.02
	(j) Other non-current assets		49.65	54.10
<b>2</b>	<b>Current assets</b>			
	(a) Inventories		-	-
	(b) Financial Assets			
	(i) Investments		-	-
	(ii) Trade receivables		64.15	51.56
	(iii) Cash and cash equivalents		3.17	8.07
	(iv) Bank balances other than (iii) above		3.55	15.57
	(v) Loans		-	-
	(vi) Others (to be specified)		-	-
	(c) Current Tax Assets (Net)		-	-
	(d) Other current assets		0.62	-
	<b>Total Assets</b>		<b>121.47</b>	<b>129.54</b>
	<b>EQUITY AND LIABILITIES Equity</b>			
	(a) Equity Share capital		336.31	336.31
	(b) Other Equity		(241.25)	(232.11)
	<b>LIABILITIES</b>			
<b>1</b>	<b>Non-current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings		2.52	2.52
	(ii) Trade payables		-	-
	(iii) Other financial liabilities (other than those		-	-
	(b) Provisions		-	-
	(c) Deferred tax liabilities (Net)		-	-
	(d) Other non-current liabilities		-	-
<b>2</b>	<b>Current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings		2.78	2.78
	(ii) Trade payables		18.96	18.48
	(iii) Other financial liabilities (other than those		-	-
	(b) Other current liabilities		2.15	1.56
	(c) Provisions		-	-
	(d) Current Tax Liabilities (Net)		-	-
	<b>Total Equity and Liabilities</b>		<b>121.47</b>	<b>129.54</b>

*Chandran*

**LIMITED REVIEW REPORT**


To  
The Board of Directors,  
M/s Pharmaids Pharmaceuticals Limited,  
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of **PHARMAIDS PHARMACEUTICALS LIMITED** for the Quarter Ended 31<sup>st</sup> December, 2018 ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above and subject to the non presentation of segment information as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG & CO  
Chartered Accountants  
FRN No. 009655S



(GIRDHARI LAL TOSHNIWAL)  
Partner  
M.No. 205140

Place : Hyderabad  
Date : 12/02/2019